Top Markets
#1 Black Phoenix Black Phoenix +865.02%
#2 Nesa Nesa +503.76%
#3 MetaDAO MetaDAO +32.63%
#4 Ontology Gas Ontology Gas +19.39%
#5 Bedrock Bedrock +18.48%
#6 Stacks Stacks +16.73%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.35%
#8 Prom Prom +14.96%
#9 Pons Pons +13.62%
#10 Utya Utya +12.77%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990
Classifica tra le azioni #1488
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Prezzo delle azioni
$66.97
Capitalizzazione di mercato
$15.62B
Variazione (1 giorno)
0.10%
Variazione (1 anno)
11.36%
Paese
CN
Scambia Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)

Categoria

Healthcare
Storico del prezzo dell'azione per Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Prezzo di chiusura più alto: $67.67 il 2026-08-01

Prezzo di chiusura più basso: $9.27 il 2023-07-01
Storico del prezzo dell'azione di Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. dal 2023 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 7.99%
2025 132.86%
2024 84.97%
2023 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.76 41.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.01K 49.43%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $139.50 450.30%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $769.67 8.30%
CH